News

Conceptualizing risk among patients with traumatic brain injury requires clinicians to consider multiple factors including neuroanatomic and cognitive dysfunction, and psychosocial impairment.

Despite advances in neurology, a silent epidemic of older adults who sustain a TBI is growing. The authors provide tools and tips for a geriatric approach to treatment.

Neurology Times' inaugural Special Report explores TBI, providing key insights and practical strategies as well as focused approaches to clinical care.

The CAM options described here may help prevent trauma-related neurodegeneration over the long term.

The FDA announced that eszopiclone, zaleplon, and zolpidem will have a new boxed warning for rare, but serious injuries and deaths as a result of complex sleep behaviors caused by the medications.

While the overall link is only suggestive, new findings from a preliminary study have implied that there may be a link between sugar-sweetened beverage consumption and a higher disability status in MS.

The co-founder and CEO of Onera Health spoke about how Onera plans to revamp sleep diagnostics with its smart band-aid patches.

When combined with high-intensity statin therapy, treatment with alirocumab resulted in a 27% reduction in stroke risk, and 15% reduction in all-cause mortality.

Currently, there are no disease-modifying medications for Huntington disease and few interventions available to effectively alleviate symptoms, while the lack of indicators of pathobiological processes at the molecular level has limited the ability to prove efficacy and safety in clinical trials.

The chair of Applied Neuroimaging and head of Neuroimaging Sciences and Edinburgh Imaging at the University of Edinburgh spoke about what the physician community needs to know about utilizing isosorbide mononitrate and cilostazol for lacunar stroke.

Although highly efficacious DMTs have improved outcomes for a growing number of patients, the majority of people with MS are still subjected to the day-to-day consequences of the disease’s symptoms, which often have a more debilitating effect on the patient than the disease itself.

Neurology News Network for the week ending April 27, 2019.

An escalating, combination dose of isosorbide mononitrate and cilostazol was shown to be well tolerated, with 72% of patients achieving full or ≥50% partial doses, the primary outcome, by the end of the 8-week treatment period.

The FDA issued a reminder that improper use of the Stryker Wingspan Stent System can result in an increased risk for stroke or mortality. The agency advises against using the system when the onset of symptoms is within 7 days or less of treatment or for the treatment of transient ischemic attacks.

The investigational candidate is the subject of the 2-part phase 2/3 SUNFISH trial in young adult and pediatric patients with type 2 and type 3 SMA.

The adoption of plasma NfL as a biomarker for tracking neurodegeneration would help fill a need for a less invasive, more economical biomarker.

NuPlasma yFFP was associated with improvements in complications of therapy, motor examination scores, mentation, behavior, and mood, and in activities of daily living in patients with Parkinson disease.

Over the course of approximately 3 years, Hammersmith Functional Motor Scale-Expanded and Upper Limb Module scores, as well as 6-Minute Walk Test distances, improved significantly in patients with SMA type 2 and type 3.

What do you suspect is responsible for this patient’s progressively worsening cognitive symptoms?

NeurologyLive spoke with the director of the Cleveland Clinic Lou Ruvo Center for Brain Health to learn why, despite hundreds of failed trials and therapies, there is growing excitement for what's to come.

Infants with SMA—who have elevated pNF-H levels—experienced significant drops in pNF-H levels when treated with nusinersen (Spinraza, Biogen), suggestive of pNF-H’s potential as a biomarker of disease activity and treatment response.

The Assistant Professor at the University of Alabama School of Medicine spoke about the results of a recent cohort study that found that a shorter, yet deeper therapeutic coma may be safer and more effective than the currently recommended therapeutic coma duration for refractory status epilepticus.

The study provides class 2A and Level B evidence that DOAC therapy started in a median of 5 days following ischemic stroke in patients with atrial fibrillation is beneficial compared with VKA therapy.

A prespecified futility analysis of a phase 3 study revealed that the primary endpoint of mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period is unlikely to be met.

Alder stated that it expected to receive a PDUFA action date within 74 days of the submission for eptinezumab and is planning a commercial launch of the anti-CGRP agent by early 2020.

Research from the past decade suggests that sigma-1 receptors and their encoding gene, SIGMAR1, together act as a therapeutic target for patients with dementia.

The chief executive officer of Alder Biopharmaceuticals detailed where the intravenous anti-CGRP treatment will fit into the marketplace and how the migraine prevention therapy will make an impact in treating patients.